The agency selected three contractors to help develop an IT system that will analyze the performance of drugs and vaccines on the market. The Food and Drug Administration awarded contracts worth up to $225 million combined to three companies Monday to help develop an IT system that will track and analyze the performance of drugs, vaccines and other pharmaceuticals on the market.Acumen, LLC of Burlingame, California; Dovel Technologies, LLC of McLean, Virginia; and IQVIA Government Solutions, Inc., of Fairfax, Virginia each secured $75 million indefinite delivery, indefinite quantity contracts to provide data, tools and infrastructure solutions to the agency for its Biologics Effectiveness and Safety (BEST) Initiative.The initiative, started by the FDAs Center for Biologics Evaluation and Research in 2017, aims to expand the data and infrastructure capabilities to evaluate the effectiveness and safety of post-market biological products, specifically vaccines, blood and blood products, tissues and advanced therapeutics.The contractors will be tasked with helping build an infrastructure able to to provide data sources and the capability and capacity to run queries and observational studies on the data sources for CBER-regulated biologic products as well as a network to analyze large-scale health care data, like administrative, claims and electronic health record data.

Source: Click here

Share this article

Facebook Comments